TG Therapeutics Inc (NASDAQ:TGTX)

16.44
Delayed Data
As of Jul 02
 -0.22 / -1.32%
Today’s Change
7.20
Today|||52-Week Range
20.00
+3.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$832.4M

Company Description

TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. The TG-1101 is a third generation, type I chimeric IgG1 monoclonal antibody with a glycoengineered Fc region designed specifically to induce higher ADCC activity in comparison to rituximab, which has been demonstrated in pre-clinical models. The TGR-1202, is an orally available PI3K delta inhibitor. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
3 Columbus Circle
New York New York 10019
P:(212) 554-4484
Investor Relations:
(212) 554-4351

Employees

Shareholders

Other institutional36.05%
Mutual fund holders16.14%
Individual stakeholders10.25%

Top Executives

Michael S. WeissExecutive Chairman, President & CEO
Sean A. PowerCFO, Secretary, Treasurer & CAO
Robert NiecestroExecutive Vice President-Clinical & Regulatory
Hari MiskinHead-Business Development
Jenna A. BoscoDirector-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account